Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BHT003D
- Development stage
- Preclinical
- Lead developer
- Bio-Hybrid Therapeutics
- Administration
- Topical
01
Overview
BHT003D is a conceptual topical biologic medication being developed by Bio-Hybrid Therapeutics for the treatment of atopic dermatitis, specifically targeting less severe use cases. As a pipeline candidate, it is designed to expand the company's portfolio of allergy-focused biologic solutions, which aim to address allergic responses at the source rather than merely managing symptoms. Currently, BHT003D is in the conceptual stage of development with no specified mechanism of action or clinical phase.
Beyond the preview
Go deeper on BHT003D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BHT003D.